Lamotrigine (All indications) updated on 04-22-2025

Polydactyly

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S8908
R30107		 Källén (Lamotrigine) (Indications NOS), 2013 Poly/syndactyly early pregnancy population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes 1.33 [0.27;3.90] 3/1,084   3,084/1,575,847 3,087 1,084
ref
Total 1 studies 1.33 [0.35;5.05] 3,087 1,084
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Källén (Lamotrigine) (Indications NOS), 2013Källén, 2013 1 1.33[0.27; 3.90]3,0871,0840%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate0.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Lamotrigine) (Indications NOS;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.33[0.35; 5.05]3,0871,084 -NAKällén (Lamotrigine) (Indications NOS), 2013 1 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.33[0.35; 5.05]3,0871,084 -NAKällén (Lamotrigine) (Indications NOS), 2013 1 Tags Adjustment   - Yes  - Yes 1.33[0.35; 5.05]3,0871,084 -NAKällén (Lamotrigine) (Indications NOS), 2013 1 All studiesAll studies 1.33[0.35; 5.05]3,0871,084 -NAKällén (Lamotrigine) (Indications NOS), 2013 10.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.33[0.35; 5.05]3,0871,084 -NAKällén (Lamotrigine) (Indications NOS), 2013 10.510.01.0